TY  - JOUR
A1  - Zhou, Xiang
A1  - Rasche, Leo
A1  - Kortüm, K. Martin
A1  - Danhof, Sophia
A1  - Hudecek, Michael
A1  - Einsele, Hermann
T1  - Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
T2  - Frontiers in Immunology
N2  - In the last few years, monoclonal antibodies (mAbs) such as elotuzumab and daratutumab have brought the treatment of multiple myeloma (MM) into the new era of immunotherapy. More recently, chimeric antigen receptor (CAR) modified T cell, a novel cellular immunotherapy, has been developed for treatment of relapsed/refractory (RR) MM, and early phase clinical trials have shown promising efficacy of CAR T cell therapy. Many patients with end stage RRMM regard CAR T cell therapy as their “last chance” and a “hope of cure”. However, severe adverse events (AEs) and even toxic death related to CAR T cell therapy have been observed. The management of AEs related to CAR T cell therapy represents a new challenge, as the pathophysiology is not fully understood and there is still no well-established standard of management. With regard to CAR T cell associated toxicities in MM, in this review, we will provide an overview of experience from clinical trials, pathophysiology, and management strategies.
KW  - CAR T cell
KW  - clinical trial
KW  - multiple myeloma
KW  - toxicity
KW  - pathophysiology
KW  - management
Y1  - 2020
UR  - https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/21991
UR  - https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-219911
SN  - 1664-3224
VL  - 11
ER  -